The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents a study evaluating the influence of splicing mutations (SPM) on outcomes in patients with myelofibrosis (MF) secondary to polycythemia vera (PV) or essential thrombocythemia (ET). Full molecular sequencing revealed distinct mutation patterns between patients with primary MF and post-ET/post-PV MF. Despite these differences, survival outcomes were comparable, with SRSF2 mutations exerting the most significant impact on survival. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: MorphoSys US
